Charles Lin

• Led 40+ identification and evaluation of external business opportunities, including Out/In-Licensing, NewCo, Co-Development and Investments, with a focus on innovative therapeutics across North America and Europe. • Established and managed relationships with partners ranging from multinational corporations (MNCs) and mid-sized biotechs to start-ups and academic institutions in the US and EU. • Cultivated key external partnerships, identified prospective collaborators, and maintained a deep understanding of industry trends and developments.

• Led 10+ cross-functional projects from proposal development to deal closure and alliance management, collaborating with internal cross-function teams, while providing regular updates to the executive team. • Developed 80+ persuasive business cases for prioritized external opportunities, using robust analyses, key assumptions and risks, and internal and external input to provide clear recommendations to the management team. • Represented cooperation at industry, investor, and partnering conferences, and foster strong relationships with a diverse range of pharmaceutical and biotechnology industry participants. • Facilitated collaboration across R&D, Clinical, Regulatory, Operations, Finance, and Legal teams with regular executive reporting.

• Facilitated in 20+ investments for internal and external (VC/PE) entities across new tech ventures spanning early- to late-stage privately held companies in North America, Europe, Asia, and Australia. • Participated in global investment and M&A by deal sourcing, underwriting investment opportunities, providing scientific insights, cross-functional Due Diligence, and generating Due Diligence reports across target markets. • Identified 50+ transformational technologies while shaping emerging science to address unmet needs ranging from ideas, IPs, research articles, conferences, presses, and events. • Managed existing life science, biomedical and biotech project pipelines while developing new business opportunities, leading In-Licensing, distribution, and partnership projects from initial to deal negotiation, and closing.

• Advised 2 FDA regulatory applications and 7 novel product innovations and strategy design initiatives. • Managed 40+ life science/biomedical projects. • Established collaborative research and selected valuable patents from joint research for evaluation and incubation. • Led a team to create the innovation strategy aligned with company global goals and local operations.

• Led 3 research proposals and School of Medicine’s annual research program review panel, completed fundraising for the NIH (R01 & R21) and University of Connecticut. • Served over 2 years as reviewer in the School of Medicine’s Annual Research Program review panel. • Delivered 4 significant presentations at professional conferences, focused on the molecular function of host genes that influences viral pathogenesis and disease outcomes. • Designed, proposed, and executed research projects to investigate host antiviral immunity and pathogenic mechanisms of viral infection at in vivo and in vitro levels.

• Led 2 NIH and 1 NSF grants to investigate biomolecular interaction mechanisms and diagnostic designs. • Benchmarked the 1st intracellular fluorescence resonance energy transfer using in-house protein-protein interaction library. • Selected as Howard Hughes Medical Institute (HHMI) Scientific Teaching Fellow with demonstrated commitment to mentoring biomedical research. • Mentored and trained 14 laboratory members across different education levels (PhDs comprised 50% of trainees).

• Introduced innovative new methods for characterizing protein-protein interactions. • Demonstrated novel PPI applicability in discovering functions of yet unknown proteins in the human and animal genome.

• Evaluated the efficiency of novel adjuvant for commercialized vaccines against influenza virus (won Excellent Thesis Award, top 3%). • Developed 3 novel genetically engineered vaccine candidates against RNA and DNA viruses which causes substantial financial and economic loss globally. • Reported and generated the genetic diversity of 8 emerging, re-emerging viruses that are of public health importance. • Characterized the structure, function, and molecular mechanisms of 7 structural and nonstructural virus genome proteins.

Harvard Business School’s digital transformation initiatives are designed to empower participants with cutting-edge tools, resources, and skills essential for success in a rapidly evolving digital landscape. By leveraging innovative technologies such as AI, data analytics, and virtual collaboration platforms, the programs provide an immersive and accessible learning experience. Participants gain hands-on exposure to digital strategies, leadership frameworks, and organizational change methodologies, equipping them to navigate and lead effectively in the era of digital disruption. Emphasizing practical applications, the program fosters adaptability and resilience, enabling participants to drive meaningful impact within their organizations and industries. I am fortunate to collaborate with visionary peer leaders from around the globe, exchanging ideas, growing, and learning together in this transformative journey.